Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Pediatrics

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Effects of infant weight gain on subsequent allergic outcomes in the first 3 years of life

  • Evelyn Xiu-Ling Loo1,
  • Anne Goh2,
  • Izzuddin Bin Mohd Aris1, 3,
  • Oon Hoe Teoh4,
  • Lynette Pei-Chi Shek3, 13,
  • Bee Wah Lee3,
  • Yiong Huak Chan5,
  • Mya Thway Tint9,
  • Shu-E Soh1,
  • Seang-Mei Saw6,
  • Peter Gluckman1, 7,
  • Keith M Godfrey8, 12,
  • Yap-Seng Chong1, 9,
  • Fabian Yap10,
  • Michael S Kramer9, 14,
  • Hugo Van Bever3, 13 and
  • Yung Seng Lee1, 3, 11Email author
BMC PediatricsBMC series – open, inclusive and trusted201717:134

https://doi.org/10.1186/s12887-017-0890-0

Received: 2 November 2016

Accepted: 23 May 2017

Published: 2 June 2017

Abstract

Background

The association between early weight gain and later allergic outcomes has not been well studied. We examined the relation between weight gain and the subsequent development of allergic outcomes in the first 36 months of life in a Singapore birth cohort.

Methods

In repeated visits in the first 15 months, we measured infant weight and administered questionnaires ascertaining allergic outcomes. At ages 18 and 36 months, we administered skin prick tests (SPTs) to inhalant and food allergens.

Results

At 18 months, 13.5% had a positive SPT, 3.5% had wheeze and a positive SPT, 3.9% had rhinitis and a positive SPT, and 6.1% had eczema and a positive SPT. Higher weight gain from 6 to 9 months, 9 to 12 months and 12 to 15 months were independently associated with a reduced risk of developing a positive SPT at 18 months (p-trend ≤0.03). At 36 months, 23.5% had a positive SPT, 11.9% had wheeze and a positive SPT, 12.2% rhinitis and a positive SPT, and 11.5% eczema and a positive SPT. Higher weight gain from 12 to 15 months was associated with a reduced risk of developing a positive SPT at 36 months (p-trend <0.01). No significant associations were observed between weight gain in any period and wheeze, rhinitis or eczema combined with a positive SPT at 18 or 36 months.

Conclusion

Higher weight gain in the first 15 months of life was associated with a reduced risk of allergen sensitization, but not with combinations of allergic symptoms.

Trial registration

NCT01174875 Registered 1 July 2010, retrospectively registered.

Keywords

ObesityAllergyAllergen sensitizationBirth cohortEarly childhood

Background

Allergic diseases and childhood obesity have increased in parallel worldwide in recent decades, suggesting a potential causal link between them [1]. Obesity is also considered a state of chronic inflammation, with activation of multiple cytokines [2]. Positive associations between obesity and allergic diseases in childhood have been reported, [35] although studies of the association between weight gain and atopy have shown inconsistent results. [6, 7].

Most previous studies have focused on older children (≥3 years), [7, 8] and knowledge is limited on the impact of early weight gain on subsequent allergic sensitization and atopic conditions (e.g., eczema, asthma, and rhinitis). [9] We hypothesized that rapid weight gain during infancy would be associated with an increased risk of developing allergic outcomes later in childhood and tested this hypothesis in the Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth cohort. To our knowledge, ours is the first study to examine the effect of weight gain in early life on allergic outcomes in an Asian population. This population has a dissimilar genetic constitution to Western populations, along with many differences in dietary and environmental exposures.

Methods

The methodology of the GUSTO study has been described previously. [10, 11] Briefly, we recruited 1247 healthy pregnant mothers who agreed to enroll their offspring for future follow-up. Interviewers gathered information on demographics, family history of allergy, social data and lifestyle factors. Anthropometric measurements were carried out in the home at 3 weeks and 3, 6, 9, 12 and 15 months of age, with examination of the child at the study clinic site at 18 and 36 months. Definitions were standardized in the questionnaires administered at 3, 6, 9, 12, 15 18, 24 and 36 months to ensure consistency during interviews and home visits. Skin prick testing (SPT) to inhalant allergens (house dust mites Dermatophagoides pteronyssinus, Dermatophagoides farinae, and Blomia tropicalis) and to food allergens (egg, peanut and cow’s milk) was carried out at the 18- and 36-month visits. All of the allergens for skin prick testing were obtained from Greer Laboratories (Lenoir, NC, USA), except for B. tropicalis, which was obtained from our in-house laboratory. SPTs were was taken to be positive if the wheal was at least 3 mm, and a child was considered as SPT-positive if any one or more of the individual tests was positive with a positive reaction to the positive control (histamine) and a negative reaction to the negative control (saline).

Subjects were shown pictures of eczema. Physician-diagnosed atopic eczema was based on a positive answer to the written question: “Has your child ever been diagnosed with eczema?”. “Wheezing” was based on a positive answer to the written question “Has your child ever wheezed?”, while “rhinitis” was based on a positive response to the question “Has your child ever had sneezing, running nose, blocked or congested nose, snoring or noisy breathing during sleep or when awake that has lasted for 2 or more weeks duration?” Study team members called the subjects who reported rhinitis to collect information on the number of episodes of rhinitis and the duration of each episode. A case prior to 18 months required a single episode that lasted for at least 4 weeks or two or more episodes each lasting at least 2 weeks. New cases of rhinitis after 18 months were defined by one or more episodes lasting at least 2 weeks.

Allergic clinical outcomes until 18 months were to the above-noted written questions in the first 18 months, combined with a positive SPT at 18 months. Allergic clinical outcomes until 36 months were defined as positive responses to the above-noted written questions in the first 36 months, combined with a positive SPT at 36 months. Children were included in the analysis if they were at risk for development of new allergic outcomes, i.e., did not have the allergic outcome before the period of weight gain analyzed. The allergic outcome was classified as absent when the answers for all visits were “no.” Family history of allergy was defined as positive if the mother, father or an older sibling ever had atopic eczema, asthma or allergic rhinitis.

Serial anthropometric measurements of weight at birth, 3 weeks, and 3, 6, 9 12 and 15 months were taken by trained research staff. Infant weight was recorded to the nearest gram using a calibrated infant scale (SECA 334 Weighing Scale, SECA Corp.). All measurements were taken in duplicate and the average used for all analyses.

Classification of breastfeeding has been previously described. [12] High breastfeeding was defined by exclusive or predominant breastfeeding for at least 4 months, with subsequent partial breastfeeding to at least 6 months, while low breastfeeding was defined as exclusive formula feeding or weaning before 3 months. Intermediate breastfeeding was defined as breastfeeding to at least 3 months but without meeting the criteria for high breastfeeding.

Ethics approval was obtained from the Domain Specific Review Board of Singapore National Healthcare Group and the Centralised Institutional Review Board of SingHealth. Informed written consent was obtained from all subjects.

Statistical analysis

Statistical analysis was carried out using IBM SPSS version 20.0 (IBM SPSS Statistics, Armonk, NY). The weight change from the initial weight at the beginning of each period to the final weight at the end of each period was calculated in kilograms and divided into quartiles. The strength of association between quartiles of weight gain and the allergic outcomes was estimated using univariable and multivariable logistic regression (adjusting for relevant covariates). Chinese and male were used as the reference categories for ethnicity and sex, respectively.

Results

Description of the study cohort

Of the 1247 mothers recruited into GUSTO, 1059 gave birth to full-term infants (gestational age ≥ 37 weeks) and were considered eligible for this study. The response rates to questions on allergic outcomes and SPT as well as schematic diagrams of the children included in the analysis are shown in Figs. 1 and 2. The main reason for non-completion of the questionnaires was the mothers’ not having been contactable and hence not having a home visit. Tables 1 and 2 compare the characteristics of those children with complete information and those with missing data. While the distribution of sex remains fairly similar between those with complete information and those with missing data, there are some differences in distribution of ethnicity and maternal education levels between them.
Fig. 1

Schematic diagram of children who completed the SPT at 18 months

Fig. 2

Schematic diagram of children who completed the SPT at 36 months

Table 1

Comparison of study children who completed questionnaires and SPT at 18 months vs other GUSTO children

 

N(%)

Subjects that complete questions on rhinitis and SPT

Excluded

P-value

Subjects that complete questions on wheeze and SPT

Excluded

P-value

Subjects that complete questions on eczema and SPT

Excluded

P-value

Subjects that complete SPT

Excluded

P-value

Gender

 Male

299 (51.2)

262 (55.2)

0.2

299.(50.3)

262 (56.5)

0.047

326 (50.9)

235 (56.1)

0.1

398 (52.0)

163 (55.4)

0.3

 Female

285 (48.8)

213 (44.8)

 

296 (49.7)

202 (43.5)

 

314 (49.1)

184 (43.9)

 

367 (48.0)

131 (44.6)

 

Ethnicity

 Chinese

352 (60.3)

253 (53.3)

0.1

363 (61.0)

242 (52.2)

<0.01

387 (60.5)

218 (52.0)

<0.01

438 (57.3)

167 (56.8)

0.8

 Malay

138 (23.6)

127 (26.7)

 

147 (24.7)

118 (25.4)

 

156 (24.4)

109 (26.0)

 

194 (25.4)

71 (24.1)

 

 Indian

94 (16.1)

95 (20.0)

 

85 (14.3)

108 (22.4)

 

97 (15.2)

92 (22.0)

 

133 (17.4)

56 (19.0)

 

Maternal Education ≥12 years

371 (64.0)

267 (57.3)

0.03

375 (63.5)

263 (57.8)

0.1

401 (63.1)

237 (57.7)

0.1

464 (61.3)

174 (60.2)

0.8

Maternal Education <12 years

209 (36.0)

199 (42.7)

 

216 (36.5)

192 (42.2)

 

234 (36.9)

174 (42.3)

 

293 (38.7)

115 (39.8)

 
Table 2

Comparison of study children who completed questionnaires and SPT at 36 months vs other GUSTO children

 

N(%)

Subjects that complete questions on rhinitis and SPT

Excluded

P-value

Subjects that complete questions on wheeze and SPT

Excluded

P-value

Subjects that complete questions on eczema and SPT

Excluded

P-value

Subjects that complete SPT

Excluded

P-value

Sex

 Male

303 (51.2)

258 (55.2)

0.2

342 (53.0)

219 (52.9)

1.00

304 (51.6)

257 (54.7)

0.3

414 (52.9)

147 (53.1)

1.00

 Female

289 (48.8)

209 (44.8)

 

303 (47.0)

195 (47.1)

 

285 (48.4)

213 (45.3)

 

368 (47.1)

130 (46.9)

 

Ethnicity

 Chinese

360 (60.8)

245 (52.5)

0.02

377 (58.4)

228 (55.1)

0.04

349 (59.3)

256 (54.5)

0.02

446 (57.0)

159 (57.4)

0.60

 Malay

139 (23.5)

126 (27.0)

 

168 (26.0)

97 (23.4)

 

152 (25.8)

113 (24.0)

 

201 (25.7)

64 (23.1)

 

 Indian

93 (15.7)

96 (20.6)

 

100 (15.5)

89 (21.5)

 

88 (14.9)

101 (21.5)

 

135 (17.3)

54 (19.5)

 

Maternal Education ≥12 years

379 (64.2)

259 (56.8)

0.02

395 (61.5)

243 (60.1)

0.70

365 (62.4)

273 (59.2)

0.3

474 (61.1)

164 (60.7)

0.90

Maternal Education <12 years

211 (35.8)

197 (43.2)

 

247 (38.5)

161 (39.9)

 

220 (37.6)

188 (40.8)

 

302 (38.9)

106 (39.3)

 

A total of 103 (13.5%) subjects had a positive SPT at 18 months, of whom 82 (7.7%) had a positive SPT to inhalant allergens while 36 (3.4%) a positive SPT to food allergens and 15 (1.4%) a positive SPT to both. Twenty one (3.5%) subjects had wheeze and a positive SPT, 23 (3.9%) rhinitis and a positive SPT, and 39 (6.1%) eczema and a positive SPT.

A total of 184 children (23.5%) had a positive SPT at 36 months; 180 (17.0%) had a positive SPT to inhalant allergens, 15 (1.4%) had a positive SPT to food allergens and 11 (1.0%) a positive SPT to both. Seventy-seven(11.9%) subjects had wheeze and a positive SPT, 72 (12.2%) rhinitis and a positive SPT, and 68 (11.5%) eczema and a positive SPT.

Associations between weight gain and allergic outcomes

As shown in Table 3, increasing weight gain quartile from 6 to 9 months, 9 to 12 months and 12 to 15 months was associated with a reduced risk of developing a positive SPT at 18 months (p-trend ≤0.03). Comparing extreme weight gain quartiles between 6 to 9 months, infants in the highest quartile had a reduced risk of a positive SPT at 18 months [adjusted odds ratio 0.3 (0.1–0.7)] compared with the lowest quartile, after adjustment for baseline weight at the beginning of the period, family history of allergy, ethnicity, sex, maternal education levels, breastfeeding, maternal height and maternal BMI. Similarly, the highest quartile of weight gain between 12 to 15 months was associated with a reduced risk of a positive SPT at 18 months vs the lowest quartile [adjusted odds ratio 0.4 (0.2–0.8)]. A similar but nonsignificant association was observed for weight gain from 9 to 12 months.
Table 3

Associations between infant weight gain and allergic outcomes by 18 months

 

Quartile 1

Quartile 2

Quartile 3

Quartile 4

Q u arti l e 1

Quartile 2

Q uartile 3

Q u arti le 4

 

Period of weight gain

Allergic outcomes

N(%)

N(%)

N(%)

N(%)

Reference

group

Adjusted OR (95% CI)

Adjusted OR (95% CI)

Adjusted OR (95% CI)

p-trend

0 to 3 months

Wheeze with a positive skin prick test

1 (0.6)

5 (3.0)

2 (1.3)

11 (7.6)

1.00

1.4 (0.1–17.9)

1.3 (0.1–18.6)

4.5 (0.4–53.4)

0.2

Prolonged rhinitis with a positive skin prick test

3 (1.9)

1 (0.7)

2 (1.4)

7 (5.2)

1.00

0.2 (0.0–3.0)

0.2 (0.0–3.4)

1.7 (0.2–14.5)

0.2

Atopic eczema with a positive skin prick test

5 (3.0)

4 (2.4)

2 (1.3)

9 (6.2)

1.00

0.4 (0.1–2.4)

0.3 (0.0–2.2)

0.8 (0.1–4.9)

0.8

Positive skin prick test

28 (14.1)

25 (14.0)

12 (6.7)

34 (19.3)

1.00

1.1 (0.5–2.4)

0.6 (0.2–1.4)

1.7 (0.7–3.9)

0.5

3 to 6 months

Wheeze with a positive skin prick test

5 (3.2)

4 (2.5)

2 (1.3)

3 (1.9)

1.00

1.1 (0.1–8.5)

0.5 (0.0–6.5)

1.8 (0.3–12.4)

0.7

Prolonged rhinitis with a positive skin prick test

0 (0)

4 (2.8)

4 (2.9)

4 (2.9)

1.00

#

#

#

#

Atopic eczema with a positive skin prick test

5 (3.1)

3 (1.8)

1 (0.7)

3 (2.0)

1.00

1.6 (0.2–10.6)

#

1.0 (0.1–8.7)

0.6

Positive skin prick test

31 (17.6)

30 (16.8)

21 (12.4)

14 (8.3)

1.00

1.4 (0.7–3.0)

0.9 (0.4–2.0)

0.6 (0.2–1.4)

0.1

6 to 9 months

Wheeze with a positive skin prick test

3 (1.9)

2 (1.2)

5 (3.1)

3 (2.0)

1.00

0.3 (0.0–3.6)

1.6 (0.3–9.7)

0.6 (0.1–7.9)

0.9

Prolonged rhinitis with a positive skin prick test

2 (1.4)

1 (0.7)

3 (2.1)

1 (0.8)

1.00

1.0 (0.1–12.6)

0.7 (0.1–9.6)

0.7 (0.0–11.4)

0.8

Atopic eczema with a positive skin prick test

5 (3.2)

4 (2.6)

1 (0.7)

1 (0.7)

1.00

2.4 (0.3–16.7)

0.6 (0.0–7.0)

#

0.3

Positive skin prick test

30 (17.9)

26 (15.4)

22 (13.2)

16 (9.7)

1.00

0.5 (0.2–1.1)

0.5 (0.2–1.0)

0.3 (0.1–0.7)

<0.01

9 to 12 m o n th s

Wheeze with a positive skin prick test

3 (1.9)

1 (0.6)

3 (1.9)

0 (0)

1.00

0.7 (0.1–9.6)

1.8 (0.2–16.1)

#

0.5

Prolonged rhinitis with a positive skin prick test

1 (0.7)

0 (0)

0 (0)

2 (1.3)

1.00

#

#

#

#

Atopic eczema with a positive skin prick test

3 (2.0)

2 (1.3)

1 (0.7)

3 (2.0)

1.00

0.6 (0.0–7.0)

0.4 (0.0–4.9)

#

0.2

Positive skin prick test

34 (20.0)

26 (15.8)

12 (7.3)

20 (11.3)

1.00

0.9 (0.4–1.8)

0.4 (0.2–0.96)

0.5 (0.2–1.2)

0.03

12 to 15 months

Wheeze with a positive skin prick test

0 (0)

3 (1.7)

0 (0)

1 (0.6)

1.00

#

#

#

#

Prolonged rhinitis with a positive skin prick test

0 (0)

0 (0)

0 (0)

0 (0)

1.00

#

#

#

#

Atopic eczema with a positive skin prick test

1 (0.6)

0 (0)

0 (0)

2 (1.2)

1.00

#

#

#

#

Positive skin prick test

32 (17.7)

25 (14.3)

19 (11.2)

20 (11.3)

1.00

0.7 (0.3–1.4)

0.5 (0.2–1.0)

0.4 (0.2–0.8)

<0.01

Weight gain at 0–3 months adjusted for birthweight for gestational age and sex, family history of allergy, ethnicity, sex, gestational age, breastfeeding, maternal education levels, maternal height and maternal BMI Weight gain (Kg) at 3–6 months, 6–9 months, 9–12 months and 12–15 months were adjusted for the baseline weight at the beginning of the period, family history of allergy, ethnicity, sex, breastfeeding, maternal education levels, maternal height and maternal BMI

#Not estimable, owing to insufficient number of children with studied outcomes Effects of infant weight gain on allergic outcomes

Values in italics have reached statistical significance with p-value <0.05

Further sub-analysis of the associations between increasing weight gain and positive SPT to inhalant allergens and to food allergens showed a similar trend. Increasing weight gain from 6 to 9 months was associated with a reduced risk of developing positive SPT to inhalant allergens, in particular to Dermatophagoides pteronyssinus, Dermatophagoides farinae(p-trend <0.05 Additional file 1: Tables S1 and S2). Increasing weight gain from 9 to 12 months was associated with a reduced risk of developing positive SPT to food allergens (p-trend =0.03, Additional file 1: Table S1).

No significant associations were observed between weight gain in any period and wheeze, allergic rhinitis or atopic eczema.

As shown in Table 4, increasing weight gain quartile from 12 to 15 months was associated with a reduced risk of developing a positive SPT at age 36 months (p-trend <0.01). Comparing extreme weight gain quartiles between 12 to 15 months, infants in the highest quartile had a reduced risk of a positive SPT at 18 months [adjusted odds ratio 0.4 (0.2–0.8)] compared with the lowest quartile. Further sub-analysis of the association between increasing weight gain and positive SPT to inhalant allergens showed a similar trend. Increasing weight gain from 12 to 15 months was associated with a reduced risk of developing positive SPT to inhalant allergens, in particular to Dermatophagoides pteronyssinus, Dermatophagoides farinae (p-trend <0.05, Additional file 1: Tables S3 and S4). Increasing weight gain from 3 to 6 months and 9 to 12 months was associated with a reduced risk of developing a positive SPT to food allergens at 36 months (p-trend <0.05, Additional file 1: Table S3).
Table 4

Associations between infant weight gain and allergic outcomes by 36 months

 

Quartile 1

Quartile 2

Quartile 3

Quartile 4

Quartile 1

Quartile 2

Quartile 3

Quartile 4

 

Period of weight gain

Allergic outcomes

N (%)

N (%)

N (%)

N (%)

Reference

group

Adjusted OR (95% CI)

Adjusted OR (95% Adjusted OR

CI) (95% CI)

Adjusted OR (95% Adjusted

p-trend

0 to 3 months

Wheeze with a positive skin prick test

11 (6.7)

15 (9.3)

19 (11.8)

19 (13.1)

1.00

1.6 (0.6–4.5)

1.8 (0.6–5.4)

1.3 (0.4–4.0)

0.7

Rhinitis with a positive skin prick test

10 (6.7)

9 (6.3)

16 (10.6)

24 (17.6)

1.00

0.9 (0.3–3.1)

1.3 (0.4–4.3)

1.7 (0.5–6.0)

0.3

Atopic eczema with a positive skin prick test

5 (3.4)

10 (6.7)

9 (6.6)

10 (7.3)

1.00

1.9 (0.5–7.1)

1.4 (0.3–5.8)

1.1 (0.3–4.9)

0.9

Positive skin prick test

34 (17.4)

36 (20.0)

45 (24.7)

59 (31.7)

1.00

1.3 (0.7–2.6)

1.6 (0.8–3.3)

1.6 (0.8–3.3)

0.2

3 to 6 months

Wheeze with a positive skin prick test

12 (7.6)

14 (8.4)

7 (4.5)

16 (11.0)

1.00

1.3 (0.4–3.9)

0.3 (0.1–1.5)

2.6 (0.9–7.3)

0.2

Rhinitis with a positive skin prick test

9 (6.3)

22 (14.7)

10 (7.0)

13 (10.3)

1.00

6.7 (1.4–31.8)

3.2 (0.6–16.4)

4.5 (0.9–22.2)

0.3

Atopic eczema with a positive skin prick test

7 (4.9)

6 (4.0)

2 (1.4)

7 (5.3)

1.00

0.8 (0.2–3.1)

0.2 (0.0–1.6)

1.0 (0.3–3.8)

0.8

Positive skin prick test

43 (23.8)

41 (22.7)

46 (25.8)

35 (21.1)

1.00

1.1 (0.6–2.2)

1.1 (0.6–2.1)

0.9 (0.5–1.8)

0.8

6 to 9 months

Wheeze with a positive skin prick test

12 (7.6)

11 (6.7)

13 (8.5)

8 (5.3)

1.00

0.4 (0.1–1.4)

0.7 (0.2–2.0)

1.1 (0.3–3.5)

0.9

Rhinitis with a positive skin prick test

12 (8.3)

13 (9.2)

12 (8.6)

9 (7.1)

1.00

0.5 (0.1–1.8)

0.6 (0.2–2.0)

0.5 (0.1–1.9)

0.3

Atopic eczema with a positive skin prick test

6 (4.2)

7 (5.1)

4 (3.0)

2 (1.6)

1.00

1.4 (0.4–5.8)

0.8 (0.2–3.6)

0.7 (0.1–4.3)

0.6

Positive skin prick test

40 (23.3)

45 (25.9)

37 (22.2)

34 (20.4)

1.00

0.5 (0.3–0.96)

0.5 (0.3–1.0)

0.5 (0.3–1.0)

0.06

9 to 12 m o n th s

Wheeze with a positive skin prick test

14 (8.9)

7 (4.5)

8 (4.9)

9 (5.5)

1.00

0.5 (0.1–1.6)

0.7 (0.2–2.1)

0.2 (0.0–0.8)

0.04

Rhinitis with a positive skin prick test

11 (8.2)

8 (6.0)

9 (6.1)

17 (11.7)

1.00

0.5 (0.1–2.3)

0.7 (0.2–2.7)

1.2 (0.3–4.2)

0.7

Atopic eczema with a positive skin prick test

4 (2.9)

1 (0.7)

6 (4.6)

4 (2.9)

1.00

#

1.3 (0.3–5.7)

0.5 (0.1–3.1)

0.9

Positive skin prick test

43 (24.9)

39 (23.8)

37 (21.4)

39 (22.9)

1.00

0.9 (0.5–1.6)

0.8 (0.4–1.5)

0.5 (0.3–1.1)

0.1

12 to 15 months

Wheeze with a positive skin prick test

6 (3.6)

10 (6.0)

8 (4.8)

8 (4.6)

1.00

1.7 (0.5–5.5)

0.5 (0.1–2.1)

1.1 (0.3–4.0)

0.6

Rhinitis with a positive skin prick test

8 (6.1)

15 (10.7)

11 (7.6)

9 (6.0)

1.00

1.3 (0.3–5.2)

1.3 (0.3–5.1)

0.8 (0.2–3.3)

0.7

Atopic eczema with a positive skin prick test

4 (2.7)

5 (3.3)

2 (1.4)

3 (1.9)

1.00

1.3 (0.3–6.3)

#

0.8 (0.1–5.4)

0.3

Positive skin prick test

49 (27.8)

40 (23.1)

37 (20.9)

37 (20.6)

1.00

0.6 (0.3–1.0)

0.4 (0.2–0.8)

0.4 (0.2–0.8)

<0.01

Weight gain at 0–3 months adjusted for birthweight for gestational age and sex, family history of allergy, ethnicity, gestational age, sex, breastfeeding, maternal education levels, maternal height and maternal BMI. Weight gain (Kg) at 3–6 months, 6–9 months, 9–12 months and 12–15 months were adjusted for the baseline weight at the beginning of the period, family history of allergy, ethnicity, sex, breastfeeding, maternal education levels, maternal height and maternal BMI

#Not estimable, owing to insufficient number of children with studied outcomes

Values in italics have reached statistical significance with p-value <0.5

No significant associations were obtained between weight gain in any period and allergic wheeze, allergic rhinitis or atopic eczema by 36 months.

Discussion

Rapid weight gain in the first year of life among GUSTO children was associated with a reduced risk of allergen sensitization at age 18 months. Weight gain from 12 to 15 months of life reduced the risk of allergen sensitization at both 18 and 36 months. Findings from previous studies have been mixed. The PROBIT study from Belarus found no consistent associations between infant weight gain and SPT results at 6.5 years but observed an inverse association of weight gain velocity from 12 to 34 months and from 34 to 60 months. [7] In the United Kingdom, 1548 children were followed up with SPTs at 3 years; no significant associations were observed with postnatal weight gain velocity. [9] Similarly, the PIAMA birth cohort study from the Netherlands followed a subgroup (n = 1554) to 8 years and found no associations between BMI changes from 1 to 2 years and allergen-specific IgE at 8 years. [8] Finally, the SCAALA cohort study from Brazil reported a lower mean z-score for growth rate in the first 2 years of life among non-sensitized (SPT-negative) children aged 4–11 years. [6].

A possible reason for the inconsistent results of these studies is the earlier age at which SPTs were obtained in the GUSTO cohort: 18 and 36 months in our study vs 3–11 years in other cohorts. Allergen sensitization patterns are known to change with age. [13, 14] The association we observed between increased weight gain and reduced subsequent allergen sensitization may be a chance finding, however, and requires confirmation in other studies. While our observations are in agreement with studies reporting an increased sensitization to food allergens in underweight individuals, [15] other studies have reported increased food allergen sensitization in overweight individuals vs those of normal weight. [16, 17] If confirmed, one possible mechanism for the associations we observed is increased leptin secretion from adipose tissue, which could skew the immune response towards a T-helper type 1 (Th1) response, with subsequent production of pro-Th1 cytokines such as IFN-γ and IL-2 and suppressed production of pro-T-helper 2 (Th2) cytokines such as IL-4, [1820] thereby reducing allergen sensitization.

We observed a nonsignificant positive association between weight gain from 0 to 3 months and allergic wheeze (i.e., wheeze with a positive SPT) by 18 months, which is limited by the small number of subjects with allergic wheeze. An association between increasing weight gain in the first 3 months and risk of wheeze has been reported in several previous studies. [7, 21] The PROBIT study from Belarus reported that weight gain velocity between 0 to 3 months was positively associated with ever having wheezed by 6.5 years. [7] Similarly, a study from the United Kingdom found a 1-SD increase in weight gain from birth to 6 months to be associated with a statistically significant 22% increase in risk of atopic wheeze (defined as ever having wheezed by 3 years and a positive SPT at 3 years). [9].

An important strength of our study is its prospective collection of outcome data at multiple time points. A limitation, however, is that allergic symptoms were all reported by the parent (usually the mother). We therefore used the SPT as an objective assessment of allergic sensitization, both alone and in combination with common symptoms and diagnoses that may have an allergic etiology. Another limitation is low statistical power, owing to missing data from non-completion of questionnaires. It will be important to track the future development of allergic diseases and immune phenotypes in our cohort to assess whether the associations we observed persist, and whether new ones emerge at later ages.

Conclusion

Higher weight gain in the first 15 months of life was associated with a reduced risk of allergen sensitization, but not with combinations of allergic symptoms. The dissociation between SPT and clinical symptoms could be due to the less specific nature of clinical symptoms of rash, rhinitis and wheezing which could be of non-atopic origins such as viral induced.

Abbreviations

CI: 

Confidence interval

OR: 

Odds ratio

SPT: 

Skin prick test

Declarations

Acknowledgements

The co-authors acknowledge the contribution of Wei Wei Pang who classified the breastfeeding data and the the rest of the GUSTO study group which includes Kenneth Kwek, Pratibha Agarwal, Dennis Bier, Arijit Biswas, Shirong Cai, Jerry Kok Yen Chan, Cornelia Yin Ing Chee, Helen Y. H Chen, Audrey Chia, Amutha Chinnadurai, Chai Kiat Chng, Mary Foong-Fong Chong, Shang Chee Chong, Mei Chien Chua, Chun Ming Ding, Eric Andrew Finkelstein, Doris Fok, Marielle Fortier, Yam Thiam Daniel Goh, Joshua J. Gooley, Wee Meng Han, Mark Hanson, Christiani Jeyakumar Henry, Joanna D Holbrook, Chin-Ying Hsu, Hazel Inskip, Jeevesh Kapur, Birit Leutscher-Broekman, Sok Bee Lim, Seong Feei Loh, Yen-Ling Low, Iliana Magiati, Lourdes Mary Daniel, Michael Meaney, Susan Morton, Cheryl Ngo, Krishnamoorthy Niduvaje, Anqi Qiu, Boon Long Quah, Victor Samuel Rajadurai, Mary Rauff, Jenny L. Richmond, Anne Rifkin-Graboi, Allan Sheppard, Borys Shuter, Leher Singh, Wing Chee So, Walter Stunkel, Lin Lin Su, Kok Hian Tan, Soek Hui Tan, Rob M. van Dam, Sudhakar K. Venkatesh, Inez Bik Yun Wong, P. C. Wong, George Seow Heong Yeo.

Funding

This research is supported by the Singapore National Research Foundation under its Translational and Clinical Research (TCR) Flagship Programme and administered by the Singapore Ministry of Health’s National Medical Research Council (NMRC), Singapore- NMRC/TCR/004-NUS/2008; NMRC/TCR/012-NUHS/2014. This work is also supported by the National Medical Research Council, NMRC/CSA/022/2010 and NRF370062-HUJ-NUS (Project 10). Additional funding is provided by the Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A*STAR), Singapore. KMG is funded by the NIHR through the NIHR Southampton Biomedical Research Centre. The funders are not involved in the design and conduct of the study, data analysis and preparation of manuscript.

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Authors contributions

LEX was involved in the study design, acquisition of data, analysis of the data and writing of the manuscript. AIM, GA, TOH, VBHP, LBW, TMT, SSE, YF contributed to the study design, acquisition of data and writing of the manuscript. CYH provided statistical advice for the analysis of the data, was involved in the study design and contributed to the writing of the manuscript. KK, GPD, GKM, SSM and CYC contributed to the design and conceptualization of the study, acquisition of data and to the writing of the manuscript. KMS was involved in the study design, analysis of the data and critical revision of the manuscript for intellectual content. LYS supervised the research and was involved in the study design, acquisition of data, analysis of data and critical revision of the manuscript for intellectual content. All authors read and approved the final manuscript.

Competing interests

Chong YS has received reimbursement for speaking at conferences sponsored by Abbott Nutrition, Nestle, and Danone. Godfrey KM has received reimbursement for speaking at conferences sponsored by Nestle and Shek LP has received reimbursement for speaking at conferences sponsored by Danone and Nestle and consulting for Mead Johnson and Nestle.

Godfrey KM, Chong YS are part of an academic consortium that has received research funding from Abbot Nutrition, Nestle and Danone. Shek LP has received research funding from Danone.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Ethical approval was obtained from the Centralized Institutional Review Board (CIRB) of SingHealth (reference 2009/280/D) and Domain Specific Review Board (DSRB) of Singapore National Healthcare Group (reference D/09/021). Conduct of this study was based on the guidelines in the Declaration of Helsinki. Written consent was obtained from the participants.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR)
(2)
Department of Paediatrics, Allergy service, KK Women’s and Children’s Hospital
(3)
Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore
(4)
Department of Paediatrics, Respiratory Service Medicine, KK Women’s and Children’s Hospital
(5)
Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore
(6)
Saw Swee Hock School of Public Health, National University of Singapore
(7)
Liggins Institute, University of Auckland
(8)
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust
(9)
Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore
(10)
Department of Paediatric Endocrinology, KK Women’s and Children’s Hospital
(11)
Division of Endocrinology and Diabetes, Khoo Teck Puat-National University Children’s Medical Institute, National University Hospital, National University Health System
(12)
Medical Research Council Lifecourse Epidemiology Unit
(13)
Khoo Teck Puat-National University Children’s Medical Institute, National University Hospital, National University Health System
(14)
Department of Pediatrics and of Epidemiology, Biostatistics and Occupational Health, McGill University Faculty of Medicine

References

  1. Weinmayr G, Forastiere F, Buchele G, Jaensch A, Strachan DP, Nagel G, et al. Overweight/obesity and respiratory and allergic disease in children: international study of asthma and allergies in childhood (ISAAC) phase two. PLoS One. 2014;9(12):e113996.View ArticlePubMed CentralPubMedGoogle Scholar
  2. Rodriguez-Hernandez H, Simental-Mendia LE, Rodriguez-Ramirez G, Reyes-Romero MA. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol. 2013;2013:678159.View ArticlePubMed CentralPubMedGoogle Scholar
  3. Yao TC, Ou LS, Yeh KW, Lee WI, Chen LC, Huang JL, et al. Associations of age, gender, and BMI with prevalence of allergic diseases in children: PATCH study. J Asthma. 2011;48(5):503–10.View ArticlePubMedGoogle Scholar
  4. Murray CS, Canoy D, Buchan I, Woodcock A, Simpson A, Custovic A. Body mass index in young children and allergic disease: gender differences in a longitudinal study. Clin exp Allergy. 2011;41(1):78–85.View ArticlePubMedGoogle Scholar
  5. Baumann S, Lorentz A. Obesity - a promoter of allergy? Int Arch Allergy Immunol. 2013;162(3):205–13.View ArticlePubMedGoogle Scholar
  6. Matos SM, Jesus SR, Saldiva SR, Prado MS, D'Innocenzo S, Assis AM, et al. Weight gain in the first two years of life, asthma and atopy: the SCAALA cohort study. Public Health Nutr. 2014;17(11):2537–45.View ArticlePubMedGoogle Scholar
  7. Anderson EL, Fraser A, Martin RM, Kramer MS, Oken E, Patel R, et al. Associations of postnatal growth with asthma and atopy: the PROBIT study. Pediatr Allergy Immunol. 2013;24(2):122–30.View ArticlePubMed CentralPubMedGoogle Scholar
  8. Scholtens S, Wijga AH, Seidell JC, Brunekreef B, de Jongste JC, Gehring U, et al. Overweight and changes in weight status during childhood in relation to asthma symptoms at 8 years of age. J Allergy Clin Immunol. 2009;123(6):1312–8. e2View ArticlePubMedGoogle Scholar
  9. Pike KC, Crozier SR, Lucas JS, Inskip HM, Robinson S, Roberts G, et al. Patterns of fetal and infant growth are related to atopy and wheezing disorders at age 3 years. Thorax. 2010;65(12):1099–106.View ArticlePubMed CentralPubMedGoogle Scholar
  10. Soh SE, Lee SS, Hoon SW, Tan MY, Goh A, Lee BW, et al. The methodology of the GUSTO cohort study: a novel approach in studying pediatric allergy. Asia Pac Allergy. 2012;2(2):144–8.View ArticlePubMed CentralPubMedGoogle Scholar
  11. Soh SE, Tint MT, Gluckman PD, Godfrey KM, Rifkin-Graboi A, Chan YH, et al. Cohort profile: growing up in Singapore towards healthy outcomes (GUSTO) birth cohort study. Int J Epidemiol. 2014;43(5):1401–9.View ArticlePubMedGoogle Scholar
  12. Cai S, Pang WW, Low YL, Sim LW, Sam SC, Bruntraeger MB, et al. Infant feeding effects on early neurocognitive development in Asian children. Am J Clin Nutr. 2015;101(2):326–36.View ArticlePubMedGoogle Scholar
  13. Simpson A, Tan VY, Winn J, Svensen M, Bishop CM, Heckerman DE, et al. Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. Am J Respir Crit Care med. 2010;181(11):1200–6.View ArticlePubMedGoogle Scholar
  14. Kim HY, Shin YH, Yum HY, Jee HM, Jang SJ, Yoon JW, et al. Patterns of sensitisation to common food and inhalant allergens and allergic symptoms in pre-school children. J Paediatr Child Health. 2013;49(4):272–7.View ArticlePubMedGoogle Scholar
  15. Van Gysel D, Govaere E, Verhamme K, Doli E, De Baets F. Body mass index in Belgian schoolchildren and its relationship with sensitization and allergic symptoms. Pediatr Allergy Immunol. 2009;20(3):246–53.View ArticlePubMedGoogle Scholar
  16. Chen Y, Rennie D, Cormier Y, Dosman J. Association between obesity and atopy in adults. Int Arch Allergy Immunol. 2010;153(4):372–7.View ArticlePubMedGoogle Scholar
  17. Visness CM, London SJ, Daniels JL, Kaufman JS, Yeatts KB, Siega-Riz AM, et al. association of obesity with IgE levels and allergy symptoms in children and adolescents: results from the National Health and Nutrition examination survey 2005-2006. J Allergy Clin Immunol. 2009;123(5):1163–9. 9 e1-4Google Scholar
  18. Iikuni N, Lam QL, Lu L, Matarese G, La Cava A. Leptin and inflammation. Curr Immunol rev. 2008;4(2):70–9.View ArticlePubMed CentralPubMedGoogle Scholar
  19. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394(6696):897–901.View ArticlePubMedGoogle Scholar
  20. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110(8):1093–103.View ArticlePubMed CentralPubMedGoogle Scholar
  21. Sonnenschein-van der Voort AM, Jaddoe VW, Raat H, Moll HA, Hofman A, de Jongste JC, et al. Fetal and infant growth and asthma symptoms in preschool children: the generation R study. Am J Respir Crit Care med. 2012;185(7):731–7.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement